Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 966,428 | 812,688 | 866,394 | 819,975 | 496,580 |
| Marketable Securities | 1,728,076 | 1,626,694 | 1,326,012 | 1,615,589 | 1,377,815 |
| Receivables | 405,308 | 327,787 | 237,963 | 198,571 | 602,413 |
| Inventories | 78,509 | 89,146 | 128,962 | 86,363 | 75,202 |
| TOTAL | $3,295,285 | $2,982,697 | $2,692,247 | $2,808,576 | $2,614,777 |
| Non-Current Assets | |||||
| PPE Net | 502,784 | 526,057 | 523,494 | 501,958 | 465,029 |
| Investments And Advances | 68,593 | 49,391 | 49,390 | 40,891 | 40,725 |
| Other Non-Current Assets | 373,321 | 271,735 | 281,228 | 291,879 | 286,530 |
| TOTAL | $944,698 | $847,183 | $854,112 | $834,728 | $792,284 |
| Total Assets | $4,239,983 | $3,829,880 | $3,546,359 | $3,643,304 | $3,407,061 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 88,415 | 55,519 | 98,094 | 73,426 | 51,966 |
| Accrued Expenses | 887,472 | 713,013 | 545,460 | 395,174 | 355,909 |
| Other current liabilities | 113,018 | 54,991 | 40,289 | 37,079 | 13,316 |
| TOTAL | $1,186,272 | $967,786 | $767,915 | $695,710 | $585,270 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | 675,697 | 191,278 |
| Deferred Revenues | 55,481 | 102,753 | 42,105 | 149,483 | 127,207 |
| Other Non-Current Liabilities | 2,986,623 | 2,894,563 | 2,742,876 | 1,531,334 | 1,389,172 |
| TOTAL | $2,986,623 | $3,082,738 | $2,936,667 | $2,359,391 | $1,805,544 |
| Total Liabilities | $4,172,895 | $4,050,524 | $3,704,582 | $3,055,101 | $2,390,814 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 129,457 | 125,946 | 124,131 | 120,211 | 117,002 |
| Common Shares | 1,293 | 1,259 | 1,240 | 1,202 | 1,164 |
| Retained earnings | -7,287,748 | -7,009,591 | -6,569,349 | -5,438,193 | -4,585,369 |
| Other shareholders' equity | -34,518 | -23,375 | -44,654 | -33,259 | -43,622 |
| TOTAL | $67,088 | $-220,644 | $-158,223 | $588,203 | $1,016,247 |
| Total Liabilities And Equity | $4,239,983 | $3,829,880 | $3,546,359 | $3,643,304 | $3,407,061 |